Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-Angiogenic Agent by Rossi, Isabella & Nwariaku, Faculty Advisor, Fiemu
Illinois Wesleyan University
Digital Commons @ IWU
John Wesley Powell Student Research
Conference 2009, 20th Annual JWP Conference
Apr 18th, 9:00 AM - 10:00 AM
Response of Anaplastic Thyroid Tumors to VEGF-
Trap, an Anti-Angiogenic Agent
Isabella Rossi
Illinois Wesleyan University
Fiemu Nwariaku, Faculty Advisor
University of Texas-Southwestern Medical Center
Follow this and additional works at: http://digitalcommons.iwu.edu/jwprc
This Event is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty
Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by
the faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.
©Copyright is owned by the author of this document.
Isabella Rossi and Fiemu Nwariaku, Faculty Advisor, "Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-
Angiogenic Agent" (April 18, 2009). John Wesley Powell Student Research Conference. Paper 23.
http://digitalcommons.iwu.edu/jwprc/2009/posters/23
THE JOHN WESLEY POWELL STUDENT RESEARCH CONFERENCE - APRIL 2009 
Poster Presentation P45 
RESPONSE OF ANAPLASTIC THYROID TUMORS TO VEGF-TRAP, 
AN ANTI-ANGIOGENIC AGENT 
Isabella Rossi and Fiemu Nwariaku* 
Biology Department, Illinois Wesleyan University and 
University of Texas Southwestern Medical Center 
Vascular Endothelial Growth Factor (VEGF) is the major pro angiogenic factor secreted by tumor 
cells. VEGF causes endothelial cell proliferation, migration, and survival, leading to the 
formation of new blood vessels that are essential for tumor growth and metastases. Anti-VEGF 
therapy involving an anti-VEGF monoclonal antibody has been successfully used to treat a 
variety of cancers. However, this approach has met with mixed results. A recently developed 
antibody, VEGF-Trap, was developed to improve the efficacy of anti-VEGF strategies. VEGF­
Trap is a synthetic protein composed of the VEGF-binding domains VEGF Receptor 1 
(VEGFRl) and VEGFR2, resulting in a higher binding affinity for VEGF than the monoclonal 
antibody. This study determined the effect of VEGF-Trap in anaplastic thyroid carcinoma, an 
aggressive form of cancer with high mortality and metastases rates. Mice bearing anaplastic 
tumors showed improved survival when treated with VEGF-Trap. The size of the tumors, in 
addition to the microvessel density, significantly decreased. Additionally, the results indicated 
compensatory VEGF production as well as an increase in macrophage density. Overall, the 
study showed anaplastic thyroid cancer to be susceptible to treatment with VEGF -Trap. 
Potential resistance of tumor blood vessels to anti-VEGF therapy is hypothesized to be conferred 
by pericytes, which provide survival signals for blood vessels. Therefore, a dual targeting of 
both endothelial cells and pericytes by combining VEGF-trap with an anti-PDGF therapy may 
prove to be a more efficient anti-angiogenic therapy for anaplastic thyroid cancer 
